Seaweed Extract Added to Standard Care for Ulcerative Colitis
Tests a seaweed-derived fucoidan added to usual care in adults with ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis
Key facts
- Where
- Lahore, PakistanSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07786389, who can take part
Where in Pakistan
- Allama Iqbal Medical collegeLahore, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Allama Iqbal Medical College
- Trial code
- NCT07786389
- Record updated
- 26 August 2026
- Original description
What is the research question being addressed? Does combining Turbinaria ornata-derived fucoidan with standard therapy lead to a significantly higher rate of gut health restoration-defined by increased fecal short-chain fatty acid (butyrate/acetate) levels, reduced fecal calprotectin, and improved stool consistency-compared to standard therapy alone in Ulcerative Colitis patients? Type of study: Interventional Study design: Randomized controlled trial Masking: Participants Control: Placebo Assignment: Parallel Purpose: Other Adjuvant / Add-On Therapy (Complementary Prebiotic Strategy) Study Phase: Phase1Read full original descriptionShow less
Effects of Brown Algae (Turbinaria Ornata) Derived Fucoidan on Intestinal Inflammation and Gut Health in Ulcerative Colitis Patients
What is the research question being addressed? Does combining Turbinaria ornata-derived fucoidan with standard therapy lead to a significantly higher rate of gut health restoration-defined by increased fecal short-chain fatty acid (butyrate/acetate) levels, reduced fecal calprotectin, and improved stool consistency-compared to standard therapy alone in Ulcerative Colitis patients? Type of study: Interventional Study design: Randomized controlled trial Masking: Participants Control: Placebo Assignment: Parallel Purpose: Other Adjuvant / Add-On Therapy (Complementary Prebiotic Strategy) Study Phase: Phase1
Inclusion: Male and female patients aged between 18-64 years; Active mild to moderate diagnosed cases of uc; Voluntarily agreeing to participate and providing informed consent; Exclusion Criteria:; Other autoimmune disorders and chronic diseases; Patient with Clotting problems; Patients using oral/intravenous steroids, leukotriene antagonists, immunosuppressant's, systemic photo chemotherapy, immunotherapy, allergen-specific immunotherapy, or Chinese herbal medicine within one month before enrolment; Patient unable to take the trial supplements as scheduled or cooperate in filling out the questionnaire and taking a blood test; Patients with a history of allergy; Patients suffering from serious infection requiring hospitalization assessed by a clinician; Severe organ dysfunction (e.g., heart failure, liver failure, liver cirrhosis, or renal failure assessed by a clinician; Pregnant women or those preparing for pregnancy, and those in lactation; Patient with hypothyroidism; Patients with a history of allergy to Soy; Acute severe (fulminant) UC.